Prostaglandin E1 analogues for chronic hepatitis B
References
Additional references
Demets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. [MEDLINE: PMID:3616287]
DerSimonian R, Lair N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. [MEDLINE: PMID:3802833]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. [MEDLINE: PMID: 9310563]
Fabbri A, Bianchi G, Brizi M, Bugianesi E, Magalotti D, Zoli M, et al. Effects of systemic prostaglandin E1 on hepatic amino acid‐nitrogen metabolism in patients with cirrhosis. Hepatology 1998;27(3):815‐21. [MEDLINE: PMID: 9500712]
Flisiak R, Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B. Hepato‐Gastroenterology 1997;44(17):1419‐25.
Flisiak R, Prokopowicz D. One year follow‐up of patients treated with misoprostol in acute phase of viral hepatitis B. Prostaglandins and Other Lipid Mediators 2000;60(4‐6):161‐5. [MEDLINE: PMID: 10751646]
Greig PD, Woolf GM, Sinclair SB, Abecassis M, Strasberg SM, Taylor BR, et al. Treatment of liver graft nonfunction with prostaglandin E1. Transplantation 1989;48(3):447‐53. [MEDLINE: PMID: 2675405]
Hoofnagle JH, Carithers RL, Shapira C, Ascher N. Fulminant hepatitc failure: summary of a workshop. Hepatology 1995;21(1):240‐52. [MEDLINE: PMID: 7806160]
ICH 2000. Safety Pharmacology Studies for Human Pharmaceuticals. The ICH guideline reached Step 4 of the ICH process in November 2000. http://www.ich.org/cache/compo/276‐254‐1.html (accessed 8 September 2002).
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghn DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [MEDLINE: PMID: 8721797]
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. [MEDLINE: PMID: 11730399]
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one‐year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. The New England Journal of Medcine 1998;339(2):61‐8. [MEDLINE: PMID: 9654535]
Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. Journal of Gastroenterology and Hepatology 2000;15(Suppl):E53‐E60. [MEDLINE: PMID: 10921383]
Lim SP, Andrews FJ, O'Brien PE. Acetaminophen‐induced microvascular injury in the rat liver: protection with misoprostol. Hepatology 1995;22(6):1776‐81. [MEDLINE: PMID: 7489988]
Purcell RH. The discovery of the hepatitis virus. Gastroenterology 1993;104(4):955‐63. [MEDLINE: PMID: 8385046]
Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 2001;286(20):2546‐7. [MEDLINE: PMID: 7823387]
WHO 2002a. Hepatitis B. Fact sheet WHO/204. Revised October 2000. www. who.int (accessed 21 August 2002).
Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha‐interferon treatment in patients with hepatitis B e antigen‐positive chronic hepatitis B. A meta‐analysis. Annals of Internal Medicine 1993;119(4):312‐23. [MEDLINE: PMID: 8328741]
Wong F, Massie D, Hsu P, Dudley F. The dose‐dependent effect of misoprostol on indomethacin‐induced renal dysfunction in well compensated cirrhosis. American Journal of Gastroenterology 1995;90(9):1465‐70. [MEDLINE: PMID: 7661171]
